Earnings summaries and quarterly performance for ZimVie.
Executive leadership at ZimVie.
Vafa Jamali
Detailed
President and Chief Executive Officer
CEO
HK
Heather Kidwell
Senior Vice President, Chief Legal, Compliance and Human Resources Officer and Corporate Secretary
IK
Indraneel Kanaglekar
Senior Vice President, Chief Commercial Officer
RH
Richard Heppenstall
Executive Vice President, Chief Financial Officer and Treasurer
Board of directors at ZimVie.
Research analysts who have asked questions during ZimVie earnings calls.
DS
David Saxon
Needham & Company
3 questions for ZIMV
Also covers: ALC, ALGN, ATEC +11 more
Matthew Miksic
Barclays PLC
2 questions for ZIMV
Also covers: ABT, ATEC, BAX +15 more
AS
Anderson Schock
B. Riley Securities
1 question for ZIMV
Also covers: ANIK, CLPT, ELMD +8 more
DF
Dylan Finley
B. Riley Securities
1 question for ZIMV
Also covers: XRAY
Kevin Caliendo
UBS
1 question for ZIMV
Also covers: AHCO, ALGN, AMWL +15 more
Matt Miksic
Barclays Investment Bank
1 question for ZIMV
Also covers: ABT, ATEC, BAX +14 more
William McMahon
Barclays
1 question for ZIMV
Recent press releases and 8-K filings for ZIMV.
ZimVie Acquisition by ARCHIMED Completed
ZIMV
M&A
Delisting/Listing Issues
Takeover Bid
- ARCHIMED, an investment firm focused on healthcare industries, has completed its previously announced acquisition of ZimVie Inc..
- Pursuant to the terms of the transaction, ZimVie stockholders are entitled to receive $19.00 in cash for each share of ZimVie common stock owned.
- As a result of the transaction completion, ZimVie’s common stock no longer trades on the NASDAQ stock exchange.
Oct 20, 2025, 1:00 PM
ZimVie Stockholders Approve Acquisition by ARCHIMED
ZIMV
M&A
Proxy Vote Outcomes
Delisting/Listing Issues
- ZimVie Inc. stockholders approved the acquisition by an affiliate of ARCHIMED at a special meeting held on October 10, 2025. The Merger Agreement Proposal received 20,615,874 votes for, 29,686 against, and 55,748 abstentions, with approximately 73.38% of outstanding shares represented at the meeting.
- The merger is expected to close on October 20, 2025, subject to the satisfaction of all conditions. Upon completion, ZimVie will no longer be publicly held, and its common stock will be delisted from the Nasdaq Stock Market.
- Stockholders also approved, on an advisory (non-binding) basis, the compensation for named executive officers in connection with the merger.
Oct 10, 2025, 8:31 PM
ZimVie Inc. Provides Supplemental Merger Disclosures Amid Stockholder Litigation
ZIMV
M&A
Legal Proceedings
Proxy Vote Outcomes
- ZimVie Inc. entered into a Merger Agreement on July 20, 2025, to be acquired by Zamboni Parent Inc., with the transaction subject to stockholder approval.
- The company is facing three lawsuits and additional demand letters from purported stockholders alleging material omissions in the definitive proxy statement related to the merger.
- To mitigate litigation risks, ZimVie is voluntarily providing supplemental disclosures to the proxy statement, while asserting the allegations are without merit.
- These supplemental disclosures will not alter the $19.00 per share merger consideration or the October 10, 2025, date for the Special Meeting of stockholders.
- Centerview's financial analysis, as part of the supplemental disclosures, indicated implied per share equity value ranges of $14.00 to $18.75 (Selected Public Company Analysis) and $17.00 to $21.25 (Selected Precedent Transaction Analysis).
Oct 3, 2025, 8:34 PM
ZimVie Announces Acquisition and Q2 2025 Financial Results
ZIMV
M&A
Guidance Update
Earnings
- ZimVie Inc. will report its second quarter 2025 financial results and file its Quarterly Report on Form 10-Q after market close on Wednesday, July 30, 2025.
- The company has entered into a definitive agreement to be acquired by an affiliate of ARCHIMED for $19.00 in cash per share.
- This transaction is expected to close by year-end 2025, pending stockholder and regulatory approvals, after which ZimVie will become a privately held company and its shares will no longer be publicly traded.
- Due to the pending acquisition, ZimVie will not host a conference call for the second quarter and has withdrawn its fiscal 2025 guidance.
Jul 25, 2025, 12:00 PM
ZimVie Enters Exclusive Distribution Agreement with Osstem Implant for China Market
ZIMV
New Projects/Investments
- ZimVie Inc. has signed a strategic distribution agreement with Osstem Implant Co., Ltd. to expand its global presence in the dental implant market.
- This agreement grants Osstem Implant exclusive commercial responsibility for ZimVie implant systems within the growing Chinese market, which is estimated at greater than 10 million units annually.
- Osstem Implant is the market-leading provider of dental implants in China, leveraging its broad and established distribution channels.
Jul 23, 2025, 8:05 PM
ZimVie Inc Q1 2025 Financial Results & Full Year Guidance
ZIMV
Earnings
Product Launch
Guidance Update
- Net Sales for Q1 2025 were $112.0M, down 5.2% from Q1 2024 .
- Adjusted EBITDA increased by $5.1M to $17.6M, reflecting both a 41% improvement and a 15.7% margin .
- Adjusted EPS rose to $0.27, marking a 238% increase .
- The company improved its net loss to $(2.6)M with a margin of (2.3%) .
- ZimVie highlighted its market-leading dental implant portfolio with products like the TSX® and T3® PRO Implant Systems and enhanced digital dentistry solutions including RealGUIDE® 5.4 Software .
- Full year 2025 guidance projects Net Sales of $445M to $460M and Adjusted EBITDA between $65M and $70M .
- Operational improvements were driven by cost efficiency initiatives and strategic investments in innovation to support a global dental leadership position .
May 8, 2025, 8:30 PM
ZimVie Inc. Q4 2024 Financial Results & Strategic Transformation
ZIMV
Earnings
Revenue Acceleration/Inflection
Debt Issuance
Guidance Update
Strategic Transformation
- Deleveraging & Cost Reduction: Achieved a significant net debt reduction—from $437.3M in Q4 2023 to $145.5M in Q4 2024—and reduced net debt by more than $290M, underscoring strong financial discipline .
- Strategic Transformation: Completed the sale of its Spine business to become a pure-play dental company focused on dental implants, biomaterials, and digital dentistry, contributing to full-year 2024 revenue of approximately $450M .
- Robust Q4 2024 Performance: Recorded $111.5M in net sales, an improved net loss of $(9.7M) with margin tightening from 19.6% to 8.7%, alongside $18.4M in Adjusted EBITDA (up 32%) and over $21M in operating cash flow .
- Full-Year 2024 Results: Reported third party net sales of $449.7M, a net loss of $(33.8M), and adjusted diluted EPS of $0.62, highlighting operational improvements .
- FY 2025 Guidance: Projects revenue between $445M–$460M and Adjusted EBITDA of $65M–$70M, setting the stage for further margin expansion and a path to positive GAAP operating income .
Feb 26, 2025, 12:00 AM
Quarterly earnings call transcripts for ZimVie.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more